Europe’s microbiologists were able to take an early look at Beckman Coulter’s new random-access system for molecular diagnostics at the recent ECCMID meeting held in London. Here, Leanne Annereau answers some of the questions that delegates may not have had the chance to pose.
This year, the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) meeting was held at London’s Excel conference centre, and it provided an ideal opportunity for Beckman Coulter to showcase its proposed random-access system for molecular diagnostics that will see this technology arrive in the core laboratory. In this article, Leanne Annereau responds to a series of questions about Beckman Coulter and its product.
Q Molecular diagnostics is one of the most important technological advances in clinical diagnostics. And yet, historically, it has operated outside the core laboratory. What is Beckman Coulter’s approach and how will this impact on the market?
A We believe the next generation of instrumentation must increasingly resemble core laboratory automation with sample-in, answer-out capability. We have focused on what our customers told us they wanted – a fully automated, random-access analyser that functions within the routine laboratory (currently in development, pending CE compliance, and not yet available for in vitro diagnostic use).
Beckman Coulter‘s solution takes the complexity out of molecular testing and will fundamentally change where, when and how laboratories perform molecular diagnostics. We are focusing first on infectious diseases and blood virus testing and then we will expand the menu capability as we have done consistently with immunoassay.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.